Vaccine safety experts from the World Health Organization (WHO) are meeting on Tuesday to review the Oxford-AstraZeneca jab, after several European countries halted their rollouts.
There had been a number of cases in Europe of blood clots reported after the vaccine was administered.
But the numbers are below the level you would expect in the general population.
The UK medicines regulator and the WHO say there is no evidence of a link.
The European Medicines Agency (EMA) – the European Union’s medicines regulator – is also meeting on Tuesday.
It is expected to issue its decision on the continued use of the Oxford-AstraZeneca vaccination on Thursday.
About 17 million people in the EU and the UK have received a dose of the vaccine, with fewer than 40 cases of blood clots reported as of last week, said AstraZeneca.
Concerns that there could be a link led to 11 European countries temporarily suspending use of the vaccine, including Germany, France, Italy and Spain.
Other countries, such as Austria, have halted the use of certain batches of the drug as a precautionary measure.
But, Belgium, Poland, the Czech Republic and Ukraine said they would continue to administer the AstraZeneca vaccine.
In Thailand, Prime Minister Prayith Chan-ocha became the first in the country to receive the AstraZeneca inoculation.
The WHO says it’s investigating the reports of blood clots. On Monday, a spokesman said there was “no evidence” that the incidents were linked to the vaccine.
“As soon as WHO has gained a full understanding of these events, the findings and any unlikely changes to current recommendations will be immediately communicated to the public,” said WHO spokesman Christian Lindmeier.
